Innate Pharma (LTS:0EVI) Accounts Payable & Accrued Expense : €17.02 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Accounts Payable & Accrued Expense?

Innate Pharma's quarterly accounts payable & accrued expense declined from Dec. 2022 (€20.91 Mil) to Jun. 2023 (€18.99 Mil) and declined from Jun. 2023 (€18.99 Mil) to Dec. 2023 (€17.02 Mil).

Innate Pharma's annual accounts payable & accrued expense declined from Dec. 2021 (€28.57 Mil) to Dec. 2022 (€20.91 Mil) and declined from Dec. 2022 (€20.91 Mil) to Dec. 2023 (€17.02 Mil).

Innate Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Innate Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Accounts Payable & Accrued Expense Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

49.50

29.54

28.57

20.91

17.02

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															28.57	18.67	20.91	18.99	17.02

Innate Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Innate Pharma (LTS:0EVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (LTS:0EVI) Headlines

No Headlines